遠大醫藥(00512.HK)擬於未來12個月內不再進一步出售餘下的Telix的股份
格隆匯2月28日丨遠大醫藥(00512.HK)公告，其已完成出售部分集團在Telix Pharmaceuticals Limited（“Telix”，一間在澳州證券交易所及美國納斯達克上市的公司，股票代碼分別爲ASX:TLX,Nasdaq:TLX）的股權，通過場外交易出售其在Telix的約45.2%股份（4,947,181股），價值約1億4千3百萬澳元。所得款項將用於集團在未滿足需求領域的臨牀開發計劃，包括與Telix合作開展的項目。集團擬於未來12個月內不再進一步出售其持有餘下的6,000,000股Telix的股份。
於2020年11月，集團作出了2,500萬美元（相等於約3,500萬澳元）的戰略性股權投資，通過私募方式以每股1.69澳元的發行價取得20,947,181股Telix的足額繳清普通股。集團亦擁有Telix在大中華地區市場的前列腺癌、腎癌和腦癌（膠質母細胞瘤）成像和治療產品的獨家開發和商業化權利。
公司行政總裁周超先生表示：“Telix是集團重要的戰略合作夥伴。迄今爲止，Telix的首個前列腺癌顯像劑TLX591-CDx已成功在美國、澳大利亞以及加拿大等地獲批上市，同時，其在歐洲的上市申請也獲得了積極反饋，爲該產品2025年在19個國家的落地奠定了基礎。該產品2024年實現約7.83億澳元的全球銷售收入，同比增長近56%，令我們深受鼓舞。同時，Telix多款創新放射性核素偶聯藥物（RDC）的研發也在順利進行，包括TLX250-CDx向美國FDA遞交的用於腎癌成像的生物製品上市許可申請已獲受理，並已進入優先審評。因此，我們對其未來前景十分樂觀，亦因爲我們與Telix攜手爲中國市場開發用於診斷和治療腫瘤的潛在新成像劑和療法，故此亦認爲Telix具有進一步創造價值的潛力。作爲投資者，我們也很高興實現了我們最初的投資願景。我們已將我們不會在未來12個月內出售餘下所持股份的意願知會Telix，以表明我們對Telix的信心以及我們對兩間公司合作夥伴關係的持續承諾”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
